126 related articles for article (PubMed ID: 12111122)
21. A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model.
Gupta S; Termini JM; Rivas Y; Otero M; Raffa FN; Bhat V; Farooq A; Stone GW
Vaccine; 2015 Sep; 33(38):4798-806. PubMed ID: 26241951
[TBL] [Abstract][Full Text] [Related]
22. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation.
Fujii S; Liu K; Smith C; Bonito AJ; Steinman RM
J Exp Med; 2004 Jun; 199(12):1607-18. PubMed ID: 15197224
[TBL] [Abstract][Full Text] [Related]
23. Human dendritic cells activate T lymphocytes via a CD40: CD40 ligand-dependent pathway.
McLellan AD; Sorg RV; Williams LA; Hart DN
Eur J Immunol; 1996 Jun; 26(6):1204-10. PubMed ID: 8647193
[TBL] [Abstract][Full Text] [Related]
24. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.
Oosterwijk-Wakka JC; Tiemessen DM; Bleumer I; de Vries IJ; Jongmans W; Adema GJ; Debruyne FM; de Mulder PH; Oosterwijk E; Mulders PF
J Immunother; 2002; 25(6):500-8. PubMed ID: 12439347
[TBL] [Abstract][Full Text] [Related]
25. T-cell-dependent antitumor effects produced by CD40 ligand expressed on mouse lung carcinoma cells are linked with the maturation of dendritic cells and secretion of a variety of cytokines.
Tada Y; O-Wang J; Yu L; Shimozato O; Wang YQ; Takiguchi Y; Tatsumi K; Kuriyama T; Takenaga K; Sakiyama S; Tagawa M
Cancer Gene Ther; 2003 Jun; 10(6):451-6. PubMed ID: 12768190
[TBL] [Abstract][Full Text] [Related]
26. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.
Gatza E; Okada CY
J Immunol; 2002 Nov; 169(9):5227-35. PubMed ID: 12391241
[TBL] [Abstract][Full Text] [Related]
27. Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.
Asavaroengchai W; Kotera Y; Koike N; Pilon-Thomas S; Mulé JJ
Biol Blood Marrow Transplant; 2004 Aug; 10(8):524-33. PubMed ID: 15282530
[TBL] [Abstract][Full Text] [Related]
28. Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo.
Borges L; Miller RE; Jones J; Ariail K; Whitmore J; Fanslow W; Lynch DH
J Immunol; 1999 Aug; 163(3):1289-97. PubMed ID: 10415026
[TBL] [Abstract][Full Text] [Related]
29. CD40-targeted recombinant adenovirus significantly enhances the efficacy of antitumor vaccines based on dendritic cells and B cells.
Kim YS; Kim YJ; Lee JM; Han SH; Ko HJ; Park HJ; Pereboev A; Nguyen HH; Kang CY
Hum Gene Ther; 2010 Dec; 21(12):1697-706. PubMed ID: 20604681
[TBL] [Abstract][Full Text] [Related]
30. CTLA4 blockade maximizes antitumor T-cell activation by dendritic cells presenting idiotype protein or opsonized anti-CD20 antibody-coated lymphoma cells.
Hsu FJ; Komarovskaya M
J Immunother; 2002; 25(6):455-68. PubMed ID: 12439343
[TBL] [Abstract][Full Text] [Related]
31. Enhanced immunity against hepatoma induced by dendritic cells pulsed with Hsp70-H22 peptide complexes and CD40L.
Gao J; Luo SM; Peng ML; Deng T
J Cancer Res Clin Oncol; 2012 Jun; 138(6):917-26. PubMed ID: 22327301
[TBL] [Abstract][Full Text] [Related]
32. IFN-alpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells.
Luft T; Luetjens P; Hochrein H; Toy T; Masterman KA; Rizkalla M; Maliszewski C; Shortman K; Cebon J; Maraskovsky E
Int Immunol; 2002 Apr; 14(4):367-80. PubMed ID: 11934873
[TBL] [Abstract][Full Text] [Related]
33. Differential CD40/CD40L expression results in counteracting antitumor immune responses.
Murugaiyan G; Agrawal R; Mishra GC; Mitra D; Saha B
J Immunol; 2007 Feb; 178(4):2047-55. PubMed ID: 17277108
[TBL] [Abstract][Full Text] [Related]
34. Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV.
Zhang R; Zhang S; Li M; Chen C; Yao Q
Vaccine; 2010 Jul; 28(31):5114-27. PubMed ID: 20471443
[TBL] [Abstract][Full Text] [Related]
35. Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity.
Kalady MF; Onaitis MW; Emani S; Abdel-Wahab Z; Tyler DS; Pruitt SK
J Surg Res; 2004 Jan; 116(1):24-31. PubMed ID: 14732346
[TBL] [Abstract][Full Text] [Related]
36. Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma.
Knippertz I; Hesse A; Schunder T; Kämpgen E; Brenner MK; Schuler G; Steinkasserer A; Nettelbeck DM
J Immunother; 2009 Jun; 32(5):524-38. PubMed ID: 19609245
[TBL] [Abstract][Full Text] [Related]
37. Impaired ability of MHC class II-/- dendritic cells to provide tumor protection is rescued by CD40 ligation.
Hermans IF; Ritchie DS; Daish A; Yang J; Kehry MR; Ronchese F
J Immunol; 1999 Jul; 163(1):77-81. PubMed ID: 10384102
[TBL] [Abstract][Full Text] [Related]
38. Human dendritic cells discriminate between viable and killed Toxoplasma gondii tachyzoites: dendritic cell activation after infection with viable parasites results in CD28 and CD40 ligand signaling that controls IL-12-dependent and -independent T cell production of IFN-gamma.
Subauste CS; Wessendarp M
J Immunol; 2000 Aug; 165(3):1498-505. PubMed ID: 10903756
[TBL] [Abstract][Full Text] [Related]
39. Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-kappa B (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen.
Wiethe C; Dittmar K; Doan T; Lindenmaier W; Tindle R
J Immunol; 2003 Oct; 171(8):4121-30. PubMed ID: 14530334
[TBL] [Abstract][Full Text] [Related]
40. The role of CD40 ligand in costimulation and T-cell activation.
Grewal IS; Flavell RA
Immunol Rev; 1996 Oct; 153():85-106. PubMed ID: 9010720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
